- Home
- GHG vs CLLS Comparison
GHG vs CLLS Comparison
Compare GHG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- CLLS
- Stock Information
- Founded
- GHG 2004
- CLLS 1999
- Country
- GHG China
- CLLS France
- Employees
- GHG N/A
- CLLS N/A
- Industry
- GHG Hotels/Resorts
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- CLLS Health Care
- Exchange
- GHG Nasdaq
- CLLS Nasdaq
- Market Cap
- GHG 255.9M
- CLLS 240.2M
- IPO Year
- GHG 2018
- CLLS 2007
- Fundamental
- Price
- GHG $3.29
- CLLS $1.97
- Analyst Decision
- GHG
- CLLS Buy
- Analyst Count
- GHG 0
- CLLS 2
- Target Price
- GHG N/A
- CLLS $8.00
- AVG Volume (30 Days)
- GHG 23.9K
- CLLS 22.5K
- Earning Date
- GHG 11-25-2024
- CLLS 11-04-2024
- Dividend Yield
- GHG 3.07%
- CLLS N/A
- EPS Growth
- GHG 69.37
- CLLS N/A
- EPS
- GHG 0.34
- CLLS N/A
- Revenue
- GHG $208,477,725.00
- CLLS $19,635,000.00
- Revenue This Year
- GHG N/A
- CLLS $271.02
- Revenue Next Year
- GHG $8.78
- CLLS $33.48
- P/E Ratio
- GHG $9.31
- CLLS N/A
- Revenue Growth
- GHG 48.19
- CLLS N/A
- 52 Week Low
- GHG $2.31
- CLLS $0.96
- 52 Week High
- GHG $4.61
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- GHG 67.46
- CLLS 37.13
- Support Level
- GHG $3.01
- CLLS $1.88
- Resistance Level
- GHG $3.32
- CLLS $2.08
- Average True Range (ATR)
- GHG 0.18
- CLLS 0.12
- MACD
- GHG 0.07
- CLLS -0.04
- Stochastic Oscillator
- GHG 89.05
- CLLS 17.31
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.